ES 012
Alternative Names: ES-012Latest Information Update: 23 Nov 2022
Price :
$50 *
At a glance
- Originator Elpiscience Biopharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Siglec-15 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 20 Nov 2022 Preclinical trials in Cancer in China (Parenteral)
- 06 Jul 2021 ES 012 is available for licensing as of 06 Jul 2021. https://www.elpiscience.com/index.php?c=article&a=type&tid=31
- 06 Jul 2021 Early research in Cancer in China (Parenteral) before July 2021 (Elpis Bioscience pipeline, July 2021)